<DOC>
	<DOCNO>NCT02575235</DOCNO>
	<brief_summary>This study assess impact prevention sarcopenia take cetylpyridinium chloride target patient pre-sarcopenia sarcopenia age 60</brief_summary>
	<brief_title>Clinical Trial Assess Preventive Effects Cetylpyridinium Chloride Sarcopenia</brief_title>
	<detailed_description>75 people meet inclusion criterion screen test assign one three group randomization . They take medication four week doubleblind . Two study group take cetylpyridinium chloride 1.5mg , 4.5mg daily four week . Control group take placebo period . The main outcome variable measure compare respectively baseline , immediately dose end two week , four week end administration . Finally cetylpyridinium chloride verify whether preventive effect sarcopenia set appropriate dose .</detailed_description>
	<mesh_term>Sarcopenia</mesh_term>
	<mesh_term>Cetylpyridinium</mesh_term>
	<criteria>Presarcopenia A . Reduced skeletal muscle mass ( ASM/height2 ) M &lt; 7.0kg/m2 , F &lt; 5.7kg/m2 History stroke spinal cord injury Artificial joint Acute disease unstable chronic disease Phenylketonuria History myocardiac infarction Allergic contact dermatitis History drug/alcohol addiction , habitual smoker</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Sarcopenia</keyword>
	<keyword>Cetylpyridinium chloride</keyword>
</DOC>